Search Results - "Beschorner, Niklas"

  • Showing 1 - 11 results of 11
Refine Results
  1. 1

    Improved targeting of human CD4+ T cells by nanobody-modified AAV2 gene therapy vectors by Hamann, Martin V, Beschorner, Niklas, Vu, Xuan-Khang, Hauber, Ilona, Lange, Ulrike C, Traenkle, Bjoern, Kaiser, Philipp D, Foth, Daniel, Schneider, Carola, Büning, Hildegard, Rothbauer, Ulrich, Hauber, Joachim

    Published in PloS one (20-12-2021)
    “…Adeno-associated viruses (AAV) are considered non-pathogenic in humans, and thus have been developed into powerful vector platforms for in vivo gene therapy…”
    Get full text
    Journal Article
  2. 2

    CRISPR/Cas9 nickase-mediated disruption of hepatitis B virus open reading frame S and X by Karimova, Madina, Beschorner, Niklas, Dammermann, Werner, Chemnitz, Jan, Indenbirken, Daniela, Bockmann, Jan-Hendrik, Grundhoff, Adam, Lüth, Stefan, Buchholz, Frank, Wiesch, Julian Schulze zur, Hauber, Joachim

    Published in Scientific reports (03-09-2015)
    “…Current antiviral therapies cannot cure hepatitis B virus (HBV) infection; successful HBV eradication would require inactivation of the viral genome, which…”
    Get full text
    Journal Article
  3. 3
  4. 4

    Precise excision of HTLV-1 provirus with a designer-recombinase by Rojo-Romanos, Teresa, Karpinski, Janet, Millen, Sebastian, Beschorner, Niklas, Simon, Florian, Paszkowski-Rogacz, Maciej, Lansing, Felix, Schneider, Paul Martin, Sonntag, Jan, Hauber, Joachim, Thoma-Kress, Andrea K., Buchholz, Frank

    Published in Molecular therapy (05-07-2023)
    “…The human T cell leukemia virus type 1 (HTLV-1) is a pathogenic retrovirus that persists as a provirus in the genome of infected cells and can lead to adult…”
    Get full text
    Journal Article
  5. 5
  6. 6

    Improved targeting of human CD4.sup.+ T cells by nanobody-modified AAV2 gene therapy vectors by Hamann, Martin V, Beschorner, Niklas, Vu, Xuan-Khang, Hauber, Ilona, Lange, Ulrike C, Traenkle, Bjoern, Kaiser, Philipp D, Foth, Daniel, Schneider, Carola, Büning, Hildegard, Rothbauer, Ulrich, Hauber, Joachim

    Published in PloS one (20-12-2021)
    “…Adeno-associated viruses (AAV) are considered non-pathogenic in humans, and thus have been developed into powerful vector platforms for in vivo gene therapy…”
    Get full text
    Journal Article
  7. 7

    Improving Lentiviral Transduction of CD34 + Hematopoietic Stem and Progenitor Cells by Hauber, Ilona, Beschorner, Niklas, Schrödel, Silke, Chemnitz, Jan, Kröger, Nicolaus, Hauber, Joachim, Thirion, Christian

    Published in Human gene therapy. Part B. Methods (01-04-2018)
    “…The delivery of therapeutic genes for treatment of inherited or infectious diseases frequently requires lentiviral transduction of CD34 hematopoietic stem and…”
    Get more information
    Journal Article
  8. 8
  9. 9

    d(GGGT)4 and r(GGGU)4 are both HIV-1 inhibitors and interleukin-6 receptor aptamers by Magbanua, Eileen, Zivkovic, Tijana, Hansen, Björn, Beschorner, Niklas, Meyer, Cindy, Lorenzen, Inken, Grötzinger, Joachim, Hauber, Joachim, Torda, Andrew E., Mayer, Günter, Rose-John, Stefan, Hahn, Ulrich

    Published in RNA biology (01-02-2013)
    “…Aptamers are oligonucleotides that bind targets with high specificity and affinity. They have become important tools for biosensing, target detection, drug…”
    Get full text
    Journal Article
  10. 10

    G-107 Pronounced antiviral activity of next-generation LTR-specific Tre-recombinase by Schäfer, Carola, Karpinski, Janet, Hauber, Ilona, Chemnitz, Jan, Hofmann-Sieber, Helga, Nagel, Claus-Henning, Beschorner, Niklas, Buchholz, Frank, Hauber, Joachim

    “…HIV-1 integrates into the host chromosome and persists as a provirus flanked by long terminal repeats (LTRs). To date, treatment regimens primarily target the…”
    Get full text
    Journal Article
  11. 11